%0 Generic
%A R., Niikura
%A A., Yamada
%A M., Fujishiro
%A K., Tanaka
%A K., Matsuda
%A Y., Saito
%A K., Ohtsuka
%A I., Oda
%A C., Katada
%A M., Kato
%A M., Kida
%A K., Kobayashi
%A S., Hoteya
%A T., Horimatsu
%A S., Kodashima
%A T., Matsuda
%A M., Muto
%A H., Yamamoto
%A S., Ryozawa
%A R., Iwakiri
%A H., Kutsumi
%A H., Miyata
%A K., Haruma
%A K., Fujimoto
%A N., Uemura
%A M., Kaminishi
%A T., Shinozaki
%A H., Tajiri
%A K., Koike
%D 2018
%T Supplementary Material for: The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Effects_of_Direct_Oral_Anticoagulants_Warfarin_Aspirin_and_Thienopyridine_on_the_Performance_of_Immunochemical_Faecal_Occult_Blood_Tests/7315079
%R 10.6084/m9.figshare.7315079.v1
%2 https://karger.figshare.com/ndownloader/files/13514636
%K Colorectal neoplasia
%K Direct oral anticoagulant
%K Immunochemical faecal occult blood test
%X Aim: To clarify whether antithrombotic drugs affect diagnosis using the immunochemical faecal occult blood test (iFOBT) of colorectal neoplasia. Methods: Using the Japan Endoscopy Database from 8 centres between 2015 and 2017, we analyzed data about patients who were iFOBT positive and had received direct oral anticoagulants (DOAC), warfarin, aspirin or thienopyridine. One-to-one matching-analogue propensity score weighted analyses were performed to compare the positive predictive value (PPV) of all neoplasms, invasive and non-invasive colorectal cancers and adenomas between drug users and non-users. All neoplasms included invasive and non-invasive colorectal cancer, and adenomas. Results: We analyzed 197 DOAC users and 196 non-users, 153 warfarin users and 153 non-users, 408 aspirin users and 415 non-users, and 97 thienopyridine users and 97 non-users. No significant differences were observed in the PPV for all neoplasms (56.67 vs. 50.43%), invasive cancer (4.32 vs. 3.53%), non-invasive cancer (15.58 vs. 15.56%) or adenoma (53.13 vs. 48.09%) between the DOAC user and non-user groups. No significant differences were observed in the PPV for all neoplasia, invasive and non-invasive cancer, or adenoma between warfarin, aspirin and thienopyridine use and non-users. Conclusions: DOAC, warfarin, aspirin and thienopyridine use did not decrease the PPVs of the iFOBT used to evaluate all colorectal neoplasia.
%I Karger Publishers